Hero image

Help fight colorectal cancer with a simple blood test.

Join this study to help us develop a blood test that accurately and easily detects colorectal cancer (CRC).

In partnership with CCA logo
Study sites Full list of study sites
Cleveland clinic logo UPMC logo Publichealth logo
Full list of study sites

Early CRC detection saves lives.

Early detection can dramatically improve survival rates.* That’s why we are looking to validate a simple blood test for early CRC detection.
Help detect CRC early

Your participation will help us validate a new blood test for early CRC detection.

Get screened

Just get a simple blood test. No medications or treatment are part of this trial.

Get thanked

Receive our appreciation and a stipend of up to $100 for participating.

Mark W.

“Participating was simple, painless and convenient. I am excited to play a role in the development of a new, easier way to detect colon cancer.”

MARK W.HOLLYWOOD, FL

Who we’re looking for

We plan to enroll 25,000 participants.
Info image
Participants must be:
  • Between ages 45 and 85
  • Planning to undergo a standard screening colonoscopy
  • Willing to provide a blood sample and basic medical information
  • Living in the United States (except Hawaii)
  • Considered of average risk for CRC
  • Have no symptoms of CRC
Info image

Three easy steps to participate

1

Get a standard
blood draw

2

Undergo your already
planned colonoscopy

3

Receive our thanks
and your stipend

No medication or treatment is required for this study.
Participate image

Participate from anywhere

We have partnered with 100+ health care organizations with sites all around the United States*. Individuals can join through those sites, or from anywhere by enrolling online.

*except Hawaii

Frequently asked questions

  • Who is Freenome?

    Freenome, a biotechnology company, has pioneered a comprehensive platform for early cancer detection using a routine blood draw. The company combines its expertise in molecular biology with advanced computational biology and machine learning to recognize disease-associated patterns among billions of biomarkers.

  • What is the purpose of the PREEMPT CRC clinical trial?

    PREEMPT CRC is Freenome’s prospective clinical trial that is enrolling about 25,000 average-risk individuals. The trial aims to validate a blood test that can provide an accurate, convenient, and patient-friendly option to those undergoing screening for CRC and to support its submission for approval by the U.S. Food and Drug Administration.

  • Where is the clinical trial taking place?

    Eligible people across the U.S. (except for Hawaii) can participate. In response to COVID-19 and to make the trial more accessible, Freenome has implemented an approach that allows patients to enroll no matter where they live.

  • How long will the clinical trial last?

    The study is projected to be completed by the end of 2021.

  • If I participate, how will I receive my test results?

    The results of your colonoscopy will come from your doctor, in the same way it would have if you did not participate in this trial.

  • Will I be compensated?

    We will provide a stipend of up to $100 to those who enroll and complete the requirements of the study.

Carmen Guerra

"Please consider engaging in clinical research to develop the cures for tomorrow."

CARMEN GUERRA, M.D. BOARD SCIENTIFIC OFFICER
AMERICAN CANCER SOCIETY
VICE-CHAIR OF DIVERSITY AND INCLUSION
PENN MEDICINE

Together, we can fight CRC with a simple blood draw.